Advertisement

This site uses cookies to enhance your user experience. By continuing to use this site you are agreeing to our COOKIE POLICY.

ACCEPT AND CLOSE

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

Choose the ACS package that’s right for you.

C&EN Exclusive Cyber Week Deal: Join ACS by 12/4 for 25% off Premium Membership. Enjoy unlimited access to C&EN digital content, the mobile app, and receive C&EN magazine every week. Use code CYBERWEEK23 at checkout.

Already an ACS Member?  

Basic

$0 Community Associate

ACS’s Basic Package keeps you connected with C&EN and ACS.

  • Access to 6 digital C&EN articles per month on cen.acs.org
  • Weekly delivery of the C&EN Essential newsletter
JOIN NOW
Standard

$80 Regular Members

ACS’s Standard Package lets you stay up to date with C&EN, stay active in ACS, and save.

Eligibility restrictions apply. Review ACS Membership Packages to see if you qualify.

JOIN NOW
Premium

$160 Regular Members & Society Affiliates
$55 Graduate Students
$25 Undergraduate Students

ACS’s Premium Package gives you full access to C&EN and everything the ACS Community has to offer.

  • Unlimited access to C&EN’s daily news coverage on cen.acs.org
  • Weekly delivery of the C&EN Magazine in print or digital format
  • Access to our Chemistry News by C&EN mobile app
  • Significant discounts on registration for most ACS-sponsored meetings
ACS offers discounts for some countries outside the United States. This discount is shown at checkout, if applicable.

JOIN NOW

Thank you!

Your account has been created successfully, and a confirmation email is on the way.

Your username is now your ACS ID.

ENJOY UNLIMITED ACCES TO C&EN

Oncology

AstraZeneca licenses another Daiichi cancer drug

by Michael McCoy
August 2, 2020 | A version of this story appeared in Volume 98, Issue 30
Advertisement

Most Popular in Pharmaceuticals

 

AstraZeneca will pay $1 billion, plus potential milestone payments, to develop DS-1062, a cancer-fighting antibody-drug conjugate (ADC) from Daiichi Sankyo. The deal is the second between the two firms. In March 2019, AstraZeneca paid $1.35 billion to develop Enhertu, another Daiichi ADC. Both molecules use Daiichi’s DXd technology for attaching an antibody to a cytotoxic agent with a tetrapeptide linker designed to be broken down by enzymes made by tumor cells.

Article:

This article has been sent to the following recipient:

1 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.
SEE MY OPTIONS or Log In
GET MORE